SAiGENCI researcher awarded funding in latest MRFF round
A SAiGENCI project using nanotechnology has received funding in the latest round of Medical Research Future Fund (MRFF) Early-to-Mid Career Researchers funding.
Dr Yannan Yang
, Group Leader, Biomaterials and Immune Engineering Laboratory (BIEL) in the Tumour Inflammation and Immunotherapy program received $843,021聽for a preclinical study that will use nanorobotics vaccine-boosted CAR-T immunotherapy to treat a form of incurable brain cancer.
鈥淒iffuse intrinsic pontine glioma (DIPG) is a highly aggressive brain cancer,鈥 said Dr Yang.
鈥淐AR-T immunotherapy that alters T cells to target tumours is effective for certain cancers but it is yet to be applicable for solid tumours like DIPG.
鈥淲e have developed a nanorobot-based vaccines technology to improve the T cell response for solid tumours, and this research will allow us to develop and validate our findings in this space.鈥